Preclinical Drug Compound Request Program

The Takeda Preclinical Drug Compound Request Program supports research studies initiated by researchers worldwide. As part of this program, we provide investigators with certain research and marketed compounds for eligible pre-clinical studies.



Clinical Research Transparency

Takeda is committed to clinical research transparency. As a demonstration of this commitment Takeda invites you to visit our website dedicated to sharing Clinical Trial information: ClinicalTrials.Takeda.com.

ClinicalTrials.Takeda.com serves as a resource for medical professionals, patients, researchers and others interested in understanding more about Takeda's past and ongoing clinical trials by providing access to clinical trial protocol information and summary results. Through this website, Takeda seeks to provide clinical research transparency to spur scientific innovation, improve medical care and build public trust.

ClinicalTrials.Takeda.com also contains details about Takeda's clinical transparency policies and policies relating to access to investigational drugs outside of a clinical trial setting (if permitted by local laws and regulations relating to Expanded Access or compassionate use).

In addition, this site provides information about how academic researchers can access patient-level data-sets to permit secondary research through Takeda’s policies for responsible clinical trial data sharing.

Learn more

Phase 4 Studies

Takeda engages in Phase 4 clinical research to investigate real-world treatment patterns and better understand long-term risks and benefits of our medicines.

Learn more

IISRs: Investigator-Initiated Sponsored Research

Takeda provides support for unsolicited, independent clinical and basic science research that addresses important medical and scientific questions related to our compounds and therapeutic areas of interest through our Investigator-Initiated Sponsored Research (IISR) program.

Learn more


Expanded Access to Investigational Drugs

In some cases, Takeda may be able to provide patients access to its investigational drugs outside of a clinical trial if certain conditions are met.